About this document

1 s2.0 S0223523422003646 Main by Nguyễn Đức Thiện is a document available to read on EtoBox.

The study focuses on the development of precision-targeting EZH2 degraders for treating triple-negative breast cancer (TNBC), which is characterized by poor prognosis and limited treatment options. The most promising compound, U3i, demonstrates high affinity for the PRC2 complex and significantly enhances growth inhibition in TNBC cell lines compared to existing EZH2 inhibitors. U3i

Author

Nguyễn Đức Thiện

Language

EN